Early Parkinson's Disease Monotherapy With CVN424

Inclusion Criteria:

• Diagnosis of PD consistent with United Kingdom Brain Bank and Movement DisorderSociety Research Criteria for the Diagnosis of PD; must include bradykinesia withsequence effect, and motor asymmetry if no PD-type rest tremor.

• Not receiving anti-parkinsonian therapy, and not expecting to require it for theduration of the study.

• Men or women of all races who are at least 30 years at Screening.

• Modified Hoehn and Yahr ≤ 2.5 at Screening.

• Montreal Cognitive Assessment (MoCA) ≥ 26.

• Freely ambulatory at time of Screening (with/without assistive device).

• Female participants of childbearing potential and male participants with femalepartners of childbearing potential must agree to either remain abstinent or useadequate and reliable contraception throughout the study and at least 30 days afterthe last dose of study drug has been taken.

• Able and willing to give written (signed and dated) informed consent approved by aninstitutional review board, and to comply with scheduled visits, treatment plan,laboratory tests, and other study-related procedures to complete the study.

• Approved as an appropriate and suitable candidate by the Enrollment AuthorizationCommittee (EAC).

Exclusion Criteria:

• Diagnosis of secondary or atypical parkinsonism.

• Diagnosis of parkinsonian motor signs or symptoms ≥ 4 years before Screening Visit.

• Previous surgical procedure for PD.

• Prior treatment with a dopamine agonist, levodopa, monoamine oxidase B (MAOB)inhibitor, or adenosine A2A receptor antagonists for more than 28 total days priorto screening. Additional exclusionary parameters around PD treatment include:

• Treatment with a dopamine agonist within 14 days of Screening.

• Treatment with a MAOB inhibitor within 90 days of Screening.

• Current use of any antipsychotic, metoclopramide, or reserpine. If previously used,this may not have been within 28 days of Screening or 5 elimination half-lives (whichever one is longer).

• Current use of potent Cytochrome P450 (CYP) 3A4/5 inhibitors or inducers.

• Clinically significant orthostatic hypotension.

• Clinically significant hallucinations requiring antipsychotic use.

• Known autoimmune, malignancy (except basal cell carcinoma) or hematologic disease (prior or current) likely to interfere with the safe participation of theparticipant or interfere with assessment of safety or efficacy based on the opinionof the investigator and the medical monitor.

• Any clinically significant medical, surgical, or psychiatric abnormality that, inthe judgment of the Investigator, is likely to interfere with study compliance, thesafe participation of the participant or the assessment of safety or efficacy.

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greaterthan 2 times the upper limit of normal (ULN), and total bilirubin greater than 1.5times ULN.

• Participants with Gilbert's syndrome may have direct bilirubin measured and would beeligible for this study provided that direct bilirubin is ≤ 1.5 times ULN.

• Significant renal impairment as determined by estimated glomerular filtration rate (eGFR) using creatinine clearance (CrCL) as per the Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) equation of ≤ 50 milliliters per minutes (mL/min).

• Participant has an ECG, prior documentation history, or clinical evidence ofpotentially unstable heart disease, including, but not limited to the following:

1. QT interval corrected using Fridericia's formula (QTcF) > 470 milliseconds (msec) for female participants; > 450 msec for male participants

2. Complete right or left bundle branch block

3. Myocardial infarction within 1 year prior to screening, unstable angina within 6 months, or a current concern for symptomatic ischemic heart disease in theopinion of the investigator

4. Clinically significant atrial or ventricular dysrhythmia; the heart must be inpredominantly normal sinus rhythm

5. Second- or third-degree atrioventricular (AV) block

6. New York Heart Association (NYHA) Class II or higher congestive heart failure

7. Clinically significant cardiomyopathy or cardiac structural abnormality, in theopinion of the investigator

8. Any other cardiac condition that the Investigator feels may predispose theparticipant to ischemia or arrhythmia

• Current (or within past 12 months) diagnosis or history of substance abuse (excluding nicotine or caffeine) by Diagnostic and Statistical Manual of MentalDisorders 5 criteria.

• Positive urine drug screen for tetrahydrocannabinol or any drugs that may affectparticipant safety or interfere with efficacy assessments.

• Medical or recreational use of marijuana within 2 months of the Screening Visit. Useof cannabidiol (CBD) is prohibited after the Screening Visit and throughout thestudy.

• Currently active major depression as determined by Beck Depression Inventory (BDI)-II score of > 19.

• Active suicidal ideation within 1 year prior to Screening Visit as determined by apositive response to Question 4 or 5 on the C-SSRS.

• Currently lactating or pregnant, or planning to become pregnant during the study.

• Current participation in another investigational clinical study and/or receipt ofany investigational drug within 90 days prior to Screening.

• Prior use of CVN424 investigational product.

• Positive test for coronavirus disease 2019 (COVID-19). A participant who testspositive for COVID-19 will be eligible to be rescreened once result is negative.

• Positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), orhepatitis C virus (HCV) consistent with current infection.